Several mechanisms of resistance have been seen in the use of current treatments for HER2-positive solid cancers including mutations within the HER2 receptor leading to alterations in structure, thereby reducing the ability for therapies to bind and inhibit tumor development [98]. The gene discussed is ERBB2; the disease is neoplasm.